Abstract
Addition of high-dose chemotherapy (HDCT) to standard first-line treatment does not improve treatment response in patients with intermediate-risk or poor-risk metastatic germ cell tumours (GCT), according to results from a US multicentre randomised phase III study (J Clin Oncol 2007; 25: 247–56).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have